<?xml version="1.0" encoding="UTF-8"?>
<p>CEPI’s initial strategic objectives, established in 2016 (
 <xref rid="ref13" ref-type="bibr">13</xref>), were aimed at advancing vaccine candidates against each of its first priority pathogens (Lassa virus, MERS-CoV, a Nipah virus) through to evidence of safety and immunogenicity in humans (phase 2a) by 2022 and to establish a diverse portfolio of platform technologies that can accelerate development, manufacture, and clinical evaluation of vaccines in response to outbreaks of new EIDs, designated “Disease X” by WHO. In January 2019, CEPI expanded its list of priority pathogens to include chikungunya and Rift Valley fever. According to initial estimates, a minimum of $1 billion would be required to bring at least 4 EID vaccines through to the end of phase 2a trials and to fund investigational stockpiles of these in case of an international health emergency (
 <xref rid="ref16" ref-type="bibr">16</xref>).
</p>
